These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 1890154)

  • 21. Comprehensive survey of HRAS, KRAS, and NRAS mutations in proliferative thyroid lesions from an ethnically diverse population.
    Schulten HJ; Salama S; Al-Ahmadi A; Al-Mansouri Z; Mirza Z; Al-Ghamdi K; Al-Hamour OA; Huwait E; Gari M; Al-Qahtani MH; Al-Maghrabi J
    Anticancer Res; 2013 Nov; 33(11):4779-84. PubMed ID: 24222113
    [TBL] [Abstract][Full Text] [Related]  

  • 22. H-ras protooncogene mutations in human thyroid neoplasms.
    Namba H; Gutman RA; Matsuo K; Alvarez A; Fagin JA
    J Clin Endocrinol Metab; 1990 Jul; 71(1):223-9. PubMed ID: 2196280
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Prevalence of activating ras mutations in morphologically characterized thyroid nodules.
    Ezzat S; Zheng L; Kolenda J; Safarian A; Freeman JL; Asa SL
    Thyroid; 1996 Oct; 6(5):409-16. PubMed ID: 8936664
    [TBL] [Abstract][Full Text] [Related]  

  • 24. K-ras activation occurs frequently in mucinous adenocarcinomas and rarely in other common epithelial tumors of the human ovary.
    Enomoto T; Weghorst CM; Inoue M; Tanizawa O; Rice JM
    Am J Pathol; 1991 Oct; 139(4):777-85. PubMed ID: 1656759
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Radiation-associated and 'spontaneous' human thyroid carcinomas show a different pattern of ras oncogene mutation.
    Wright PA; Williams ED; Lemoine NR; Wynford-Thomas D
    Oncogene; 1991 Mar; 6(3):471-3. PubMed ID: 2011403
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Familial non-medullary thyroid carcinoma (FNMTC): analysis of fPTC/PRN, NMTC1, MNG1 and TCO susceptibility loci and identification of somatic BRAF and RAS mutations.
    Cavaco BM; Batista PF; Martins C; Banito A; do Rosário F; Limbert E; Sobrinho LG; Leite V
    Endocr Relat Cancer; 2008 Mar; 15(1):207-15. PubMed ID: 18310288
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Prevalence of Ras mutations in thyroid neoplasia.
    Esapa CT; Johnson SJ; Kendall-Taylor P; Lennard TW; Harris PE
    Clin Endocrinol (Oxf); 1999 Apr; 50(4):529-35. PubMed ID: 10468914
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Detection of activated ras oncogenes in human thyroid carcinomas.
    Suárez HG; Du Villard JA; Caillou B; Schlumberger M; Tubiana M; Parmentier C; Monier R
    Oncogene; 1988 Apr; 2(4):403-6. PubMed ID: 3283656
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Relationship between overexpression of ras p21 oncoprotein and K-ras codon 12 and 13 mutations in Turkish colorectal cancer patients.
    Akkiprik M; Celikel CA; Düşünceli F; Sönmez O; Güllüoğlu BM; Sav A; Ozer A
    Turk J Gastroenterol; 2008 Mar; 19(1):22-7. PubMed ID: 18386236
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Ras mutations are uncommon in sporadic thyroid cancer in children and young adults.
    Fenton C; Anderson J; Lukes Y; Dinauer CA; Tuttle RM; Francis GL
    J Endocrinol Invest; 1999 Nov; 22(10):781-9. PubMed ID: 10614528
    [TBL] [Abstract][Full Text] [Related]  

  • 31. ras mutations are associated with aggressive tumor phenotypes and poor prognosis in thyroid cancer.
    Garcia-Rostan G; Zhao H; Camp RL; Pollan M; Herrero A; Pardo J; Wu R; Carcangiu ML; Costa J; Tallini G
    J Clin Oncol; 2003 Sep; 21(17):3226-35. PubMed ID: 12947056
    [TBL] [Abstract][Full Text] [Related]  

  • 32. K-ras oncogene activation in adenocarcinoma of the human pancreas. A study of 82 carcinomas using a combination of mutant-enriched polymerase chain reaction analysis and allele-specific oligonucleotide hybridization.
    Hruban RH; van Mansfeld AD; Offerhaus GJ; van Weering DH; Allison DC; Goodman SN; Kensler TW; Bose KK; Cameron JL; Bos JL
    Am J Pathol; 1993 Aug; 143(2):545-54. PubMed ID: 8342602
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Prevalence of RAS point mutations in papillary thyroid carcinoma; a novel mutation at codon 31 of K-RAS.
    Cyniak-Magierska A; Brzeziańska E; Januszkiewicz-Caulier J; Jarzab B; Lewiński A
    Exp Clin Endocrinol Diabetes; 2007 Oct; 115(9):594-9. PubMed ID: 17943694
    [TBL] [Abstract][Full Text] [Related]  

  • 34. N-ras mutation in poorly differentiated thyroid carcinomas: correlation with bone metastases and inverse correlation to thyroglobulin expression.
    Basolo F; Pisaturo F; Pollina LE; Fontanini G; Elisei R; Molinaro E; Iacconi P; Miccoli P; Pacini F
    Thyroid; 2000 Jan; 10(1):19-23. PubMed ID: 10691309
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Absence of activating mutations in ras and gsp oncogenes in a cohort of nine patients with sporadic pediatric thyroid tumors.
    Pauws E; Tummers RF; Ris-Stalpers C; de Vijlder JJ; Voûte T
    Med Pediatr Oncol; 2001 Jun; 36(6):630-4. PubMed ID: 11344494
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Genetic heterogeneity of the c-K-ras locus in colorectal adenomas but not in adenocarcinomas.
    Shibata D; Schaeffer J; Li ZH; Capella G; Perucho M
    J Natl Cancer Inst; 1993 Jul; 85(13):1058-63. PubMed ID: 8515492
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Thyroid targeting of the N-ras(Gln61Lys) oncogene in transgenic mice results in follicular tumors that progress to poorly differentiated carcinomas.
    Vitagliano D; Portella G; Troncone G; Francione A; Rossi C; Bruno A; Giorgini A; Coluzzi S; Nappi TC; Rothstein JL; Pasquinelli R; Chiappetta G; Terracciano D; Macchia V; Melillo RM; Fusco A; Santoro M
    Oncogene; 2006 Aug; 25(39):5467-74. PubMed ID: 16785999
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Detection of Ki-ras oncogene mutations in normal mucosa, adenoma and adenocarcinoma of the colon].
    Wang ZY
    Zhonghua Bing Li Xue Za Zhi; 1993 Dec; 22(6):333-6. PubMed ID: 7913419
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Frequent chromosomal DNA unbalance in thyroid oncocytic (Hürthle cell) neoplasms detected by comparative genomic hybridization.
    Tallini G; Hsueh A; Liu S; Garcia-Rostan G; Speicher MR; Ward DC
    Lab Invest; 1999 May; 79(5):547-55. PubMed ID: 10334566
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Mutational screening of RET, HRAS, KRAS, NRAS, BRAF, AKT1, and CTNNB1 in medullary thyroid carcinoma.
    Schulten HJ; Al-Maghrabi J; Al-Ghamdi K; Salama S; Al-Muhayawi S; Chaudhary A; Hamour O; Abuzenadah A; Gari M; Al-Qahtani M
    Anticancer Res; 2011 Dec; 31(12):4179-83. PubMed ID: 22199277
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.